NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Third Pole Therapeutics

Third Pole Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://www.pole3.com/

Last Round

Convertible Debt

Mar 13, 2025

Total Funding Raised

$123.38M

Company Overview

Third Pole Therapeutics is a medical device company that develops innovative portable inhalation devices capable of generating nitric oxide on-demand to provide life-saving therapies for various cardiopulmonary conditions.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

inhaled nitric oxideiNOmedical devicenitric oxide generatorrespiratory supporttankless nitric oxidepulmonary hypertensionportable medical deviceneonatal intensive careNICU equipmentEMS equipmentemergency medical servicescritical care technologygas delivery systempoint-of-care therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Third Pole Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Third Pole Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Third Pole Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtMar 13, 2025
Series BFeb 12, 2024
Series BDec 14, 2022
Series BFeb 3, 2022
DebtApr 15, 2021
Series B
Mar 5, 2019

Key People

Founding team and executive leadership

Bill Athenson

Chief Executive Officer

Executive Team

Ziad Elghazzawi

Chief Technology Officer

Executive Team

Third Pole Therapeutics Investors

Notable investors and investment history

Third Pole Therapeutics investors
InvestorRounds
National Heart, Lung, and Blood InstituteSeries B, Grant
National Center for Advancing Translational SciencesSeries B
Saturn PartnersSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 12, 2024

    $55M round closed.

  • Apr 15, 2021

    $15M round led by Avenue Venture Opportunities Fund.

Third Pole Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Third Pole Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Third Pole Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range31
Year Founded2014
Last FundingMar 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.